ALKBC Stock Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.125.60 |
| 52 Week High | kr.130.25 |
| 52 Week Low | kr.73.15 |
| Beta | 0.43 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 51.14% |
| 3 Year Change | -5.21% |
| 5 Year Change | 83.09% |
| Change since IPO | 404.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALKBC | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.0% |
| 1Y | 51.1% | 5.2% | 3.0% |
Return vs Industry: ALKBC exceeded the UK Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: ALKBC exceeded the UK Market which returned 3% over the past year.
Price Volatility
| ALKBC volatility | |
|---|---|
| ALKBC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ALKBC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALKBC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,824 | Peter Halling | www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
ALK-Abelló A/S Fundamentals Summary
| ALKBC fundamental statistics | |
|---|---|
| Market cap | kr.32.91b |
| Earnings (TTM) | kr.486.00m |
| Revenue (TTM) | kr.4.82b |
67.7x
P/E Ratio6.8x
P/S RatioIs ALKBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKBC income statement (TTM) | |
|---|---|
| Revenue | kr.4.82b |
| Cost of Revenue | kr.1.79b |
| Gross Profit | kr.3.04b |
| Other Expenses | kr.2.55b |
| Earnings | kr.486.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 23, 2024
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 62.94% |
| Net Profit Margin | 10.07% |
| Debt/Equity Ratio | 10.4% |
How did ALKBC perform over the long term?
See historical performance and comparison